A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer's disease, ...

Alzheimer's disease (AD) is unique among dementias for ... with a deterministic gene or biomarker evidence only, respectively. Stage 2 is a transitional stage to mild cognitive impairment (stage ...

Opens in a new tab or window With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow progression to a more advanced stage.

Biogen abandoned the development of its antibody candidate gosuranemab in 2021, and Roche/AC Immune’s semorinemab missed the mark in the phase 2 TAURIEL trial in early-stage Alzheimer’s in 2020.

Morningstar brands and products Company Portfolio ...

Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired in the $7.3 billion Reata Pharmaceuticals buyout and kicking early-stage Alzheimer’s and Parkinson’s prospects ...